Cargando…
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress
BACKGROUND: The anticancer properties of aspirin are restricted by its gastrointestinal toxicity and its limited efficacy. Therefore, we synthesized phospho-aspirin (PA-2; MDC-22), a novel derivative of aspirin, and evaluated its chemotherapeutic and chemopreventive efficacy in preclinical models of...
Autores principales: | Huang, Liqun, Wong, Chi C, Mackenzie, Gerardo G, Sun, Yu, Cheng, Ka Wing, Vrankova, Kvetoslava, Alston, Ninche, Ouyang, Nengtai, Rigas, Basil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941604/ https://www.ncbi.nlm.nih.gov/pubmed/24575839 http://dx.doi.org/10.1186/1471-2407-14-141 |
Ejemplares similares
-
Targeting Mitochondrial STAT3 with the Novel Phospho-Valproic Acid (MDC-1112) Inhibits Pancreatic Cancer Growth in Mice
por: Mackenzie, Gerardo G., et al.
Publicado: (2013) -
Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system
por: Sun, Yu, et al.
Publicado: (2012) -
Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate
por: MURRAY, ONIKA T., et al.
Publicado: (2013) -
Phospho-Aspirin-2 (MDC-22) Inhibits Estrogen Receptor Positive Breast Cancer Growth Both In Vitro and In Vivo by a Redox-Dependent Effect
por: Huang, Liqun, et al.
Publicado: (2014) -
Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan
por: Rodriguez Lanzi, Cecilia, et al.
Publicado: (2021)